Core Viewpoint - The Hong Kong pharmaceutical outsourcing sector is experiencing a strong performance, with notable increases in stock prices for several key companies [1] Company Performance - WuXi Biologics (02269.HK) has seen a stock price increase of 4.70% [1] - Kelun Pharmaceutical (06821.HK) has risen by 4.62% [1] - Tigermed (03347.HK) has gained 1.89% [1] - WuXi AppTec (02359.HK) has increased by 1.36% [1]

Core Insights - WuXi Biologics congratulates CANbridge Pharmaceuticals on the approval of velaglucerase-beta for injection, marking it as China's first locally developed enzyme replacement therapy for Gaucher disease [1][5] Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [10][11] - The company has over 12,000 employees across multiple countries and supports 817 integrated client projects, including 21 in commercial manufacturing [11] Product Development - Velaglucerase-beta for injection is the first collaboration project between CANbridge and WuXi Biologics, utilizing WuXi's integrated technology platform to enhance yield and quality [3][5] - The project achieved over 110 times increase in overall yield and over 50% increase in specific enzyme activity, ensuring affordability for patients [3] Clinical Significance - The pivotal clinical trial for velaglucerase-beta demonstrated significant efficacy, with a statistically significant reduction in spleen volume for Gaucher disease patients [8] - Gaucher disease affects approximately 0.7 to 1.75 per 100,000 people globally, with around 3,000 patients reported in China as of 2020 [2][9] Market Impact - The approval of velaglucerase-beta represents a significant milestone in rare disease drug innovation in China, reflecting CANbridge's commitment to addressing unmet clinical needs [4][5] - CANbridge has a differentiated drug portfolio with three approved drugs and a pipeline of eight assets targeting rare diseases [15]

金融界5月12日消息，上证指数高开高走，中证港股通医疗主题指数 (港股通医疗主题，932069)上涨 0.59%，报787.2点，成交额163.51亿元。 数据统计显示，中证港股通医疗主题指数近一个月上涨14.60%，近三个月上涨10.23%，年至今上涨 17.07%。 据了解，中证港股通医疗主题指数从港股通证券范围内选取50只业务涉及医疗器械、医疗商业与服务、 制药与生物科技服务等领域的上市公司证券作为指数样本，以反映港股通内医疗领域上市公司证券的整 体表现。该指数以2018年12月31日为基日，以1000.0点为基点。 从中证港股通医疗主题指数持仓样本的行业来看，医疗商业与服务占比34.97%、制药与生物科技服务 占比31.72%、医疗器械占比12.28%、化学药占比10.50%、生物药品占比10.12%、中药占比0.42%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中 ...

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Biotech Theme Index, which opened high and is currently at 1195.47 points, reflecting a recent decline of 2.95% over the past month but an increase of 13.55% over the last three months and 13.14% year-to-date [1][2] - The index comprises 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotech services from the mainland and Hong Kong markets, serving as a benchmark for the overall performance of biotech-themed securities [1][2] - The top ten weighted companies in the index include: Hengrui Medicine (13.31%), BeiGene (10.94%), WuXi AppTec (8.63%), Mindray Medical (7.77%), WuXi Biologics (5.11%), Innovent Biologics (4.73%), CanSino Biologics (3.38%), CSPC Pharmaceutical Group (2.73%), China National Pharmaceutical Group (2.41%), and Shanghai RAAS Blood Products (1.82%) [1][2] Group 2 - The index's holdings are distributed across different market exchanges, with the Hong Kong Stock Exchange accounting for 41.35%, Shanghai Stock Exchange for 36.05%, and Shenzhen Stock Exchange for 22.61% [1][2] - In terms of industry composition, biopharmaceuticals represent 42.86%, chemical drugs 25.82%, pharmaceutical and biotech services 21.73%, and medical devices 9.59% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year, ensuring that the weight factors are updated accordingly [2]

Core Viewpoint - WuXi Biologics demonstrates a strong commitment to sustainability through its 2024 Sustainability Report, highlighting significant advancements in sustainable development and corporate governance [1][3][15] Group 1: Sustainability Commitment - The company has successfully executed its "Follow and Win the Molecule" strategies while achieving notable sustainability milestones in 2024 [2] - WuXi Biologics has achieved a 30% intensity reduction in GHG emissions and a 28% reduction in water consumption compared to baseline years [7] - The Green CRDMO solution offers up to an 80% reduction in product carbon footprint, recognized by the United Nations Global Compact [9] Group 2: Governance and Stakeholder Engagement - The company has established strong corporate governance mechanisms aligned with the United Nations Sustainable Development Goals (UN SDGs) [3][4] - WuXi Biologics actively engages with stakeholders and participates in the Pharmaceutical Supply Chain Initiative (PSCI) to uphold principles in ethics, human rights, and environmental management [4] Group 3: Community and Employee Empowerment - The company supports career development for women in STEM, with 54% of STEM positions held by female employees, surpassing industry averages [5] - In 2024, nearly 10,000 employee volunteer hours were logged in local communities, emphasizing the company's commitment to social responsibility [6] Group 4: Recognition and Future Outlook - WuXi Biologics has received multiple accolades, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices, reflecting its leadership in ESG [11] - Looking ahead, the company plans to continue prioritizing sustainability as a cornerstone of its innovation and operations, contributing to the UN Sustainable Development Goals [12]

Core Points - The China-Hong Kong-US Technology Index has shown a decline of 3.69% over the past month, an increase of 1.09% over the past three months, and a year-to-date increase of 3.43% [1] - The index is composed of high liquidity and high market capitalization technology companies listed in Hong Kong and the US, calculated using an equal-weighted method to reflect the overall performance of these companies [1] - The index's top ten holdings include companies such as SMIC (3.33%), BYD (3.15%), Xiaomi (3.1%), and Alibaba (2.59%) [1] Market Composition - The index's holdings are distributed across various exchanges, with 40.48% on the Nasdaq Global Select Market, 35.64% on the Hong Kong Stock Exchange, and 22.40% on the New York Stock Exchange [2] - In terms of industry composition, Information Technology accounts for 39.01%, Consumer Discretionary for 20.52%, Healthcare for 15.01%, and Communication Services for 13.99% [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

Financial Performance - The company achieved a revenue of RMB 18,675.4 million, representing a year-on-year growth of 9.6%, with non-COVID revenue increasing by 13.1%[10] - Gross profit increased by 12.1% year-on-year, while net profit rose by 10.5% to RMB 3,945.4 million[10] - The company's revenue for the fiscal year ended December 31, 2024, reached RMB 18,675.4 million, representing a year-on-year growth of 9.6%[19] - Gross profit increased by 12.1% year-on-year to RMB 7,650.8 million, with a gross margin of 41.0% for 2024[19] - Net profit for the year was RMB 3,945.4 million, reflecting a year-on-year increase of 10.5%[19] - The revenue from North America rose significantly to RMB 10,695.8 million, accounting for 57.3% of total revenue, compared to RMB 8,073.5 million or 47.4% in the previous year[60] - IND pre-service revenue grew by 30.7% to approximately RMB 7,062.2 million, representing 37.8% of total revenue for the year ended December 31, 2024[62] - Revenue from the top five customers decreased by 10.2% to approximately RMB 5,442.3 million, representing 29.1% of total revenue for the year ended December 31, 2024[63] - Revenue from the XDC segment increased significantly to RMB 3,944.0 million, representing 21.1% of total revenue, compared to RMB 1,906.1 million or 11.2% in the previous year[66] - Adjusted net profit for the year ended December 31, 2024, was RMB 5,396.9 million, up from RMB 4,950.4 million in 2023, reflecting a growth of 9.0%[109] - Adjusted net profit margin for 2024 was 28.9%, slightly down from 29.1% in 2023[109] - Basic adjusted earnings per share increased to RMB 1.17 in 2024 from RMB 1.13 in 2023, while diluted adjusted earnings per share rose to RMB 1.12 from RMB 1.06[109] Operational Highlights - The company added 151 integrated projects, bringing the total to 817, with late-stage clinical and non-COVID commercialization projects reaching 66 and 21, respectively[10] - The company successfully supported over 600 IND submissions during the reporting period, reducing the development time from DNA to IND for mAb projects to nine months[10] - The company completed 16 process performance qualification (PPQ) projects, achieving a PPQ success rate of over 98% for drug substance (DS) and drug product (DP) production[11] - The company has 194 ongoing ADC and other bioconjugate drug iCMC projects globally, enhancing its position in the ADC market[11] - The company has established partnerships with the top twenty global pharmaceutical companies and most large pharmaceutical companies in China, expanding its customer base[20] - The total value of uncompleted orders as of December 31, 2024, amounted to USD 18.5 billion, including USD 10.5 billion in service orders and USD 8.0 billion in potential milestone payment orders[19] - The company has successfully acquired 20 external projects during the reporting period, including 13 clinical late-stage and commercialization projects, laying a solid foundation for future revenue growth[17] Technology and Innovation - The company has advanced its proprietary WuXiBody™ platform, achieving over 50 collaborations in the development of bispecific antibodies[23] - The CRDMO platform has enabled the company to empower over 600 IND submissions, significantly reducing the development cycle from DNA to IND to just nine months[29] - The WuXia™ platform has delivered over 1,000 cell lines, supporting 150 integrated CMC projects annually, making it one of the largest platforms in the industry[30] - The WuXiUP™ platform has been applied in over 140 processes, achieving production capacities of 20 to 100 grams per liter and enabling over 10 IND approvals[32] - The WuXiUI™ platform has increased the yield of various recombinant proteins by 3 to 6 times while maintaining high product quality and significantly reducing production costs[33] - The company has developed a comprehensive technology for validating tumor-associated antigens (TAA), enabling clients to discover potential best-in-class antibody-drug conjugates (ADCs)[27] - The group has established integrated platforms targeting emerging therapeutic modalities, enhancing service offerings and driving continuous growth and innovation[40] Compliance and Quality - All three facilities in Ireland received GMP certification from the HPRA, successfully completing multiple 16,000-liter scale PPQ productions[11] - The company has completed over 1,500 GMP audits and approximately 200 EU quality authorizations since 2017, maintaining high compliance standards[11] - The company is committed to maintaining the highest compliance standards and efficient operations to contribute to the global healthcare industry[13] - The group received multiple awards for quality service and ESG practices, including the "CDMO Leadership Award" for seven consecutive years[54] Sustainability and ESG - The company has made significant progress in sustainability, receiving multiple recognitions and awards from renowned rating agencies, including inclusion in the Dow Jones Sustainability Index[14] - The group joined the Science Based Targets initiative (SBTi) and became a participant in the UN Global Compact, enhancing its ESG performance[45] Governance and Management - The company emphasizes the importance of corporate governance and strategic guidance from its board members, leveraging their diverse backgrounds in finance and biopharmaceuticals[120] - The management team is focused on expanding the company's capabilities in biopharmaceutical development and production, with a strong emphasis on innovation and technology[118] - The board's composition includes members with significant experience in investment and strategic management, which supports the company's growth objectives[121] - The company is committed to maintaining high standards of governance and oversight to ensure sustainable growth and shareholder value[123] Financial Management - The company has a comprehensive financial risk management policy outlined in the annual report, ensuring robust oversight of financial performance[140] - The company has established a robust risk management system to evaluate significant risks, including operational, financial, and regulatory risks, to ensure effective operations[157] - The company is diversifying its revenue and profit sources to reduce dependence on any single country or region, while closely monitoring external environmental changes[159] - The company faces interest rate risks related to fixed-rate bank borrowings and floating-rate deposits, and it is managing these risks through careful assessment and potential interest rate swap agreements[160] Employee and Talent Management - The total number of employees reached 12,575, including 4,383 researchers, with a key talent retention rate of approximately 95.8%[113] - The company has adopted various equity incentive plans to reward eligible participants for their contributions[114] - The company aims to attract and retain key talent through the Global Partner Share Award Plan, which was adopted on June 16, 2021[188] Shareholder Information - As of December 31, 2024, Dr. Li has a 14.44% equity stake in the company, holding 592,902,633 shares[168] - The total number of issued shares as of December 31, 2024, is 4,105,937,505 shares[169] - The total number of options available for issuance under the pre-IPO share option plan is 145,700,858 shares, which is approximately 3.55% of the total issued shares[177] - The total number of restricted shares granted during the reporting period amounted to 79,063,961 shares, with 19,806,418 shares vested and 18,155,376 shares unvested[185]

Core Insights - WuXi Biologics has successfully completed Asia's first commercial-scale Process Performance Qualification (PPQ) campaign for 5,000L single-use bioreactors, marking a significant advancement in biomanufacturing capabilities [1][3] - The company achieved a nearly 70% reduction in protein production costs per gram and a 20% increase in protein yield per batch through innovative process technologies [2][7] - The MFG20 facility's total capacity has increased from 8,000L to 23,000L by integrating three 5,000L single-use bioreactors with existing production lines [2][3] Company Achievements - WuXi Biologics has maintained a 99% production success rate over the past three years across over 300 batches of scaled production, demonstrating its leadership in commercial biomanufacturing [3] - The MFG20 facility has achieved a 100% PPQ success rate and holds ISO 14001 and ISO 45001 certifications, underscoring its operational excellence [3] - The company supports 817 integrated client projects, including 21 in commercial manufacturing, showcasing its extensive engagement in the biopharmaceutical sector [5] Sustainability and Innovation - WuXi Biologics emphasizes sustainability as a cornerstone of its long-term growth strategy, driving green technology innovations to provide advanced end-to-end Green CRDMO solutions [6] - The company is committed to fostering positive social and environmental impacts through responsible practices and collaboration with stakeholders [6]

图名先生第三位是SVP以及Head of IR,Lina,Lina Fan女士然后以及整个药物生物的IR团队那么without further delay那我把这个时间交给公司非常感谢谢谢John非常高兴给大家机会跟大家来分享我们2024年的业绩我们总体来说对2024年非常满意而且2025年是加速增长 如果熟悉我们的投资人,我非常喜欢用这一个slide来总结我们2024年的业绩。左边是我们的业务的数据,右边更多的是financial的数据。 如果看项目数,我们过去一年项目数增长17%,在这么大的一个Portfolio,近700个项目,现在增加到817个项目,相当的了不起,尤其是去年,大家也都知道,噪音还是非常大的,就是生物技术的投融资不一定那么稳健,还有别的噪音也非常大。 即使这样的情况下我们最终我们是非新冠业务的增速我们达到了13%我们管理层对这个非常满意我觉得对我们最开心的还是说我这边已经切过了你们在第几页我在第五页我们看到还是第一页样目比较我这边看到第五页怎么那么奇怪呢 好了现在第五页对现在回到第五页是吗所有人都在第五页吗对对对我这边看到第五页的OK好对我觉得去年2024年我觉得在这个大环境非常复杂的情 ...

SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. This also marks the seventh time that the company has been recognized by the organizer. Best Contract Development and Manufacturing Organization Award Best Aseptic Fill-Finish & Packaging CMO of the Year Best Aseptic Fill-Finish & ...